Stock Performance Overview: Several insurance stocks in Hong Kong experienced declines, with PING AN dropping 2.071% and AIA decreasing by 0.593%, while CHINA LIFE saw a slight increase of 0.381%.
Short Selling Activity: Notable short selling figures were reported, with PING AN having a short selling ratio of 22.857% and CHINA LIFE at 27.436%, indicating significant market speculation against these stocks.
Analyst Ratings: Most companies listed, including PING AN, CHINA LIFE, and AIA, received an "Overweight" rating, suggesting analysts are optimistic about their long-term performance despite current market fluctuations.
Market Sentiment: Goldman Sachs expressed optimism regarding AIA's growth prospects in China and Hong Kong for the current year, highlighting a positive outlook amidst the overall market challenges.
Wall Street analysts forecast 00966 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 00966 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
Wall Street analysts forecast 00966 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 00966 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
Current: 21.000
Low
Averages
High
Current: 21.000
Low
Averages
High
DBS Group Research
DBS Group Research
Buy
maintain
$23 -> $25
Al Analysis
2026-01-07
Reason
DBS Group Research
DBS Group Research
Price Target
$23 -> $25
Al Analysis
2026-01-07
maintain
Buy
Reason
The analyst rating for CHINA TAIPING (00966.HK) was maintained at "Buy" due to several key factors highlighted in the report by DBS Group Research. The target price was raised from $23 to $25, reflecting an optimistic outlook for the company. The report indicates that 2025 is seen as a transitional year for CHINA TAIPING, with over 90% of its new business being par products and a shift in investment strategy from 'high yield' to a barbell strategy. The management's positive view on growth for FY2026, following the completion of adjustments in 2025, and a focus on dividend growth to enhance core solvency capacity further support the favorable rating.
Goldman Sachs
Goldman Sachs
Neutral
to
Buy
upgrade
2025-10-10
Reason
Goldman Sachs
Goldman Sachs
Price Target
2025-10-10
upgrade
Neutral
to
Buy
Reason
The analyst rating from Goldman Sachs is influenced by several factors:
1. Recent Underperformance: Chinese insurers have underperformed since the end of July, with declines in H-/A-shares, while broader market indices like the HSI and CSI 300 Index have rallied. This underperformance is attributed to high valuation levels following a rebound in stock prices and a weak earnings growth outlook due to a high base effect in the second half of 2024.
2. Improving Risk-Reward: Looking ahead to the upcoming 3Q25 results, Goldman Sachs believes that the risk-reward profile for Chinese insurers is improving. They anticipate that 3Q25 earnings may exceed expectations, driven by gains from equity investments.
3. Growth Projections: The new business value for 2026 is expected to see double-digit growth, and the contractual service profit margin is anticipated to reach a turning point, indicating potential for future profitability.
4. Specific Insurer Outlooks: Among the insurers, Goldman Sachs expects China Life to benefit the most from market changes and yields in 3Q25, followed by China Taiping. NCI is projected to exhibit strong earnings growth, despite some lag in book value and solvency ratio compared to peers.
5. Upgrades: The broker upgraded CPIC from Neutral to Buy and China Taiping from Sell to Neutral, reflecting a more favorable outlook for these companies.
Overall, the combination of improving earnings expectations, potential growth, and specific upgrades for certain insurers contributes to the positive analyst rating.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for 00966
Unlock Now
M Stanley
M Stanley
Neutral
maintain
2025-10-10
Reason
M Stanley
M Stanley
Price Target
2025-10-10
maintain
Neutral
Reason
The analyst rating for CHINA LIFE (02628.HK) is "Neutral," with a target price adjustment from HK$21.5 to HK$22.5. This rating likely reflects a cautious outlook on the stock, possibly due to factors such as current market conditions, short selling activity (with a significant ratio of 18.065%), and overall performance trends in the insurance sector. The neutral stance suggests that while the stock may not be expected to decline significantly, there may also be limited upside potential in the near term.
Buy -> Neutral
downgrade
$21
2025-08-13
Reason
Price Target
$21
2025-08-13
downgrade
Buy -> Neutral
Reason
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
